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Point: Postprandial Glucose Levels Are a
Clinically Important Treatment Target
T
he results of the Nateglinide And
Valsartan in Impaired Glucose
Tolerance Outcomes Research
(NAVIGATOR) trial have been recently
reported (1–2). Nateglinide, a member of
the meglitinide class, which has been
shown to lower postprandial hyperglyce-
miabyincreasingtheﬁrstphaseofinsulin
secretion, was not effective in decreasing
both the new cases of diabetes and the
newcardiovasculareventsinapopulation
at high risk (1). Valsartan, an angiotensin
(AT-1)blocker,wasineffectiveoncardio-
vascular events but signiﬁcantly—even
marginally—reducedtheonsetofnewdi-
abetes (2). The negative results of nateg-
linide immediately raised the concern
aboutthepossibilitythatpostprandialhy-
perglycemiacouldbeconsideredaninde-
pendent risk factor for cardiovascular
disease (CVD) and whether its treatment
may give any advantage in the manage-
ment of diabetes (3).
Diabetologists have long debated
whetherthelackofinsulinaction(insulin
resistance) or impaired insulin secretion
represents the primary pathological
mechanism underlying type 2 diabetes.
Recent analyses conﬁrm that impaired
pancreatic -cell glucose sensitivity and
whole-body insulin sensitivity are strong
predictorsofaprogressiontohyperglyce-
mia (4). Conversely, numerous studies
have shown that acute insulin secretion
defects represent a powerful early predic-
tor of diabetes progression.
During the progression from normal
glucose tolerance to increasingly severe
type 2 diabetes, ﬁrst-phase insulin secre-
tion (FPIS) is an early casualty. Prior to
thediagnosisofdiabetes,insulinresponse
tomealtimeglucosebecomesdelayedand
blunted; eventually, it is lost (5). In a
landmark study, Polonsky et al. (5)
showed that FPIS responses were more
sluggish and less dramatic in diabetic in-
dividuals. In another analysis, a marked
and increasing loss of the early-phase
-cell secretory response to a meal chal-
lenge correlated with increasing post-
prandial hyperglycemia in a group of
individuals recently diagnosed with dia-
betes (6). Together these data indicate
that declining FPIS and postprandial hy-
perglycemia are key features of type 2
diabetes.
The relative contribution of fasting
versus postprandial glucose (PPG) to
overall glycemic exposure was a matter of
considerable controversy until recently
when inﬂuential analyses from Monnier
et al. (7,8) appeared showing that the
contribution of postprandial hyperglyce-
mia varies depending on an individual’s
degree of glycemic control. This funda-
mental insight—that postprandial glyce-
mia excursions make an ever greater
contribution to A1C as glycemic control
improves—has been conﬁrmed in other
settings(9)andhasbeenextendedtosub-
jectswhoseA1Cvaluesliewellwithinthe
normalrange(10).Basedonthisinforma-
tion, one would predict that attempts to
treat patients to target, especially when
aiming for ambitious A1C targets, will
generally fail unless PPG is controlled.
Many studies directly support this hy-
pothesis(11),includingtherecentdataof
the Treating to Target in Type 2 diabetes
(4-T) trial (12) and in particular the data
after 1 year (13), where even the conclu-
sions of the authors were, surprisingly,
different.
Thelinkbetweenpostprandialhyper-
glycemia and the risk for CVD has been
recently highlighted due to the identiﬁed
linear relationship, widely conﬁrmed in
many studies, between the risk of CVD
death and the glucose value at 2 h during
an oral glucose tolerance test (OGTT)
(11). A recent study (14) consistently
conﬁrmed postprandial hyperglycemia as
an independent risk factor for CVD in
type 2 diabetes. However, most of the ep-
idemiological data supporting this con-
cept were available from studies using the
OGTT (11). This approach raised the
concernthatbecausetheOGTTcouldnot
be considered a meal, the existing rela-
tionship between the 2-h glucose values
duringanOGTTdidnotnecessarilymean
that these subjects could have increased
postprandial hyperglycemia after a meal.
This concern has now been clariﬁed. A
strong relationship between the level of
glycemia after an OGTT and after a meal
has been demonstrated (15), particularly
in terms of peak values, thereby suggest-
ing that this issue is now over.
However, even epidemiological data
supporttheconceptthatpostprandialhy-
perglycemia is a risk factor for CVDs, the
main concern regards the need for evi-
dence that lowering postprandial hyper-
glycemia CVD can be prevented. The
Study To Prevent Non-Insulin-Depen-
dent Diabetes Mellitus (STOP-NIDDM)
trialhasshown,asapredeﬁnedsecondary
end point, that treating postprandial hy-
perglycemia may reduce the incidence of
new cardiovascular events in people with
impairedglucosetolerance(16),aﬁnding
conﬁrmed in type 2 diabetes by a meta-
analysisontheuseofacarbose(17).How-
ever, the Hyperglycemia and Its Effect
AfterAcuteMyocardialInfarctiononCar-
diovascular Outcomes in Patients With
Type 2 Diabetes Mellitus (HEART2D)
study (18) last year and the NAVIGATOR
(1) study now, have failed to conﬁrm this
ﬁnding.
What has the NAVIGATOR study
demonstrated? In my opinion, it has only
demonstrated that nateglinide does not
reduce cardiovascular events. That is all.
Unfortunately, NAVIGATOR is another
study,asistheHEART2Dstudy(18),that
doesnothelptoanswerwhetherlowering
postprandial hyperglycemia reduces the
incidence of CVD.
The HEART2D study failed to reach
the predetermined difference in post-
prandial hyperglycemia of 2.5 mmol/l,
the mean difference at the end of the
study being only 0.8 mmol/l, less than
one-third of the goal, even if signiﬁcantly
different between the two groups (18). In
the NAVIGATOR trial, nateglinide not
onlydidnotimprovepostprandialhyper-
glycemia,buttheglucoselevels2haftera
glucose challenge in the annual OGTTs
were higher in the nateglinide group than
in the placebo group (1). Furthermore,
the incidence of new diabetes was also
higher in the treated group than in the
placebo group (1).
As already suggested (19), we have to
pay attention to the level of risk in the
patients included in the studies. We have
learned that the control of hyperglycemia
may have a different impact in the pri-
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type 2 diabetes (19), inﬂuencing the sam-
plesizeofthestudy.Lookingattherecent
lessons from the Action to Control Car-
diovascular Risk in Diabetes (ACCORD)
trial (20), the Action in Diabetes and Vas-
cular Disease–Preterax and Diamicron
Modiﬁed Release Controlled Evaluation
(ADVANCE) trial (21), the Veterans Af-
fairs Diabetes Trial (VADT) (22), and the
long-term follow-up of the UK Prospec-
tive Diabetes Study (UKPDS) (23), it has
been suggested that if the control of hy-
perglycemia, both fasting (ACCORD,
ADVANCE, and VADT) or postprandial
(HEART2D), is started too late, the possi-
ble beneﬁcial effect of treating hypergly-
cemia, both fasting (UKPDS) or
postprandial (STOP-NIDDM), in a very
early stage of the disease is lost.
In NAVIGATOR, people in the pri-
mary prevention and who already suf-
fered a cardiovascular event were pooled
and evaluated together (1). This may in-
troduce another bias in the evaluation of
the results. This concept is strengthened
during the study by the need to change
the primary outcome, including a third
coprimary core cardiovascular outcome,
previously designated as a secondary out-
come(1).Tothis,wehavetoaddthevery
high rate of dropouts (1).
The authors of NAVIGATOR claim
that the paradox increase of glucose dur-
ing the OGTT in the nateglinide arm
would be a rebound effect since nateglin-
ide was not administered on the morning
that the OGTT was performed, therefore
suggesting that postprandial hyperglyce-
mia was lower during the other days of
the study (1). However, as already out-
lined by Nathan (3), “There are no direct
data to support this contention, and no
data on glycated hemoglobin are pre-
sented, other than in the subgroup that
progressed to diabetes, to support a sub-
stantialloweringofoverallglycemiclevels
with nateglinide.”
Asreportedabove,theimpactofpost-
prandial hyperglycemia on CVD is still a
matter of debate, and perhaps we will ob-
tain an answer from the Acarbose Cardio-
vascular Evaluation (ACE), a huge trial
performed in China. However, in my
opinion, what we have learned again (19)
is how complex the management of post-
prandial hyperglycemia truly is.
This is certainly an important issue
because prandial glucose regulation is an
emerging approach to treating type 2 di-
abetes (11). Mechanistic and epidemio-
logical studies indicate that PPG
signiﬁcantly contributes to overall glyce-
mic exposure (7–8). In particular, post-
prandial hyperglycemia is the most
important contributor to A1C, particu-
larly when it is lower than 7.5% (7–8).
Targeting postprandial hyperglycemia
has been largely conﬁrmed as important
for the achievement of A1C targets (24).
Paradoxically, it has been published (25)
that in type 2 diabetic patients with good
glycemic control (A1C  6.5%), further
strict glycemic control by nateglinide
(A1C of 6.1%) resulted in the regression
of carotid intima-media thickness, a use-
ful marker of cardiovascular risk.
Oxidative stress, in particular the in-
creased superoxide production at the mi-
tochondrial level, has been suggested as
the key link between hyperglycemia and
diabetic complications (26). Evidence
suggests that the same phenomenon un-
derscoresthedeleteriouseffectofoscillat-
ing glucose, leading to a more enhanced
deleterious effect of ﬂuctuating glucose
compared with constant high glucose
(27).
Postprandial hyperglycemia, which
can be considered just an aspect of the
glucose variability, produces oxidative
stress,which,inturn,inducesendothelial
dysfunction and inﬂammation (28), all
well recognized risk factors for CVD.
Considering that the speciﬁc manage-
ment of postprandial hyperglycemia is so
difﬁcult, one can wonder whether treat-
ing oxidative stress (in the right, modern
way [29]) while managing postprandial
hyperglycemia would be a good strategy.
Forinstance,anAT-1blocker,irbesartan,
has been demonstrated to reduce oxida-
tive stress, endothelial dysfunction, and
inﬂammation induced by postprandial
hyperglycemia (30), evidence which
might explain the positive effect of valsar-
tan in preventing the new onset of diabe-
tes (1).
Accumulating evidence suggests that
glucose “variability” in terms of widely
ﬂuctuating glucose may have a deleteri-
ouseffectinworseningtheprognosis,not
only for diabetic complications, but also
for several critical care situations (27).
The hypothesis that maintaining the level
of glycemia under very strict control
would be relevant in any clinical setting
is, in my opinion, stressed by the recent
evidence that glycemia in normoglycemic
people is always maintained in very nar-
row range, particularly after a meal
(31,32). One can argue that if the human
body spends so much energy to maintain
the blood glucose level under so strict a
range, it is because otherwise it could be
deleterious.
Finally, I wonder if the acronym
“NAVIGATOR” was chosen because in
the past the concept of postprandial hy-
perglycemiaasadamagingfactorwasrep-
resented with a “wave” (28). If this is the
case, this NAVIGATOR (nateglinide)
would have been good for lakes and riv-
ers, certainly not for a stormy sea (post-
prandial hyperglycemia).
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